Canary Foundation is collaborating with some of the leading cancer researchers and research centers in the world.

BC Cancer Agency, British Columbia, Canada: Canary Foundation funding supports a dedicated team, led by Dr. Brad Nelson, at the BC Cancer Agency's Trev & Joyce Deeley Research Centre, Victoria, BC, to rapidly develop serum-based assays and validate candidate biomarkers. Dr. Nelson's team supports Canary Foundation projects in four disease areas: ovary, lung, prostate and pancreas. With funding from Canary Foundation, Drs. Marilyn Borugian and Richard Gallagher at the BC Cancer Agency in Vancouver are contributing to the national Canadian Cancer Cohort by building a biomarker validation resource consisting of blood samples from healthy controls recruited through the Screening Mammography Program of BC. Canary Foundation has also funded research by Dr. Marilyn Borugian to explore mammography as an early warning sign of ovarian cancer. Backed by Canary, Dr. David Huntsman, also at the BC Cancer Agency in Vancouver, has built tissue microarrays that are used to assess candidate biomarker expression in healthy and malignant ovarian tissue. In addition, Canary Foundation supports projects led by Dr. Wan Lam and Dr. Stephen Lam at the BC Cancer Agency in Vancouver that are aimed at discovery of biomarkers of lung cancer occurring in non-smokers.

Fred Hutchinson Cancer Research Center (FHCRC), Seattle: Canary Foundation provides critical funding for a comprehensive program in the early detection of ovarian cancer at the FHCRC. Projects in the Translation and Outcomes Research Group include Dr. Nicole Urban's research in the development of blood-based assays for the early detection of ovarian cancer, Dr. Charles Drescher's efforts toward collecting tissue and blood samples from ovarian cancer patients and Dr. Martin McIntosh's investigation of biomarker levels in both patients with ovarian cancer and women free of disease. With support from Canary Foundation, Dr. Muneesh Tewari explores microRNA as a potential source of blood biomarkers for ovarian and lung cancer. Canary Foundation also funds the discovery of candidate ovarian and lung blood-based biomarkers using state of the art proteomic technology in the lab of Dr. Samir Hanash of the Molecular Diagnostics Program. With backing from Canary, Dr. Jason Chien of the Clinical Research Division is identifying epidemiologic factors associated with an increased risk for developing lung cancer among women who never smoked.

Memorial Sloan-Kettering Cancer Research Center (MSKCC), New York: Canary Foundation sponsors two projects in early detection of lung cancer at Memorial Sloan-Kettering Cancer Research Center. Dr. Harold Varmus, President and CEO of MSKCC, and colleagues are developing mouse models carrying mutations that have been shown to cause lung cancer in humans. Dr. Peter Bach, a member of the Health Outcomes Research Group at MSKCC, examines the medical history of patients who died despite annual CT screening to estimate the window of opportunity for detecting aggressive tumors and the characteristics of CT screen-detected lung tumors.

Princess Margaret Hospital, Toronto, Ontario, Canada: Canary Foundation has funded research by Dr. Patricia Shaw at the Princess Margaret Hospital investigating the characteristics of possible precursor lesions of ovarian cancer found in the fallopian tubes.

Stanford University Medical School, Stanford: Canary Foundation supports Drs. Gambhir and Willmann at the Molecular Imaging Program at Stanford in the development of molecular imaging for ovarian, lung, prostate and pancreatic tumors, which will allow us to 'see' tumors in a living subject based on specific, unique, molecular characteristics. Canary Foundation also funds Dr. Patrick Brown's research involving genomic analysis of ovarian cancer cell lines and tumor tissues as well as fallopian tube tissues to discover candidate biomarkers of early ovarian cancer. Dr. Brown also leads a project to characterize gene expression in more than 60 tissues in the healthy human body as a baseline for comparing markers of cancer. Through her Canary sponsorship, Dr. Sylvia Plevritis of the Stanford Center of Cancer Nanotechnology Excellence is creating computer models of the natural history of lung cancer to estimate the potential effectiveness of early detection interventions. Under the leadership of Dr. James Brooks, the Stanford University Medical School is participating in the Canary Foundation Prostate Active Surveillance Study.

University of British Columbia, Vancouver, British Columbia, Canada: Led by Dr. Martin Gleave, the University of British Columbia is participating in the Canary Foundation Prostate Active Surveillance Study. Canary Foundation collaborates with Dr. Dianne Miller to investigate a potential novel source of biomarkers for early detection of ovarian cancer-proximate samples, such as fluids and tissues obtained from the fallopian tubes, uterus, vagina, or cervix.

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco: Dr. Peter Carroll, Director of Clinical Services at the UCSF Helen Diller Family Comprehensive Cancer Center, is leading participation in the Canary Foundation Prostate Active Surveillance Study. Canary Foundation has also provided funding for Dr. Frank McCormick's in-depth profiling of genetic mutation in ovarian cancer cell lines.

University of Pennsylvania, Philadelphia: With support from the Canary Foundation, Dr. George Coukos is searching for tumor vasculature markers that could be used to detect early ovarian and pancreatic cancer.

University of Southern California, Los Angeles: Canary Foundation sponsors research by Drs. Peter Laird and Ite Laird-Offringa at the Norris Comprehensive Cancer Center using state of the art methylation platforms to discover and validate DNA-based biomarkers of cancer in the ovary and lung, respectively.

University of Texas, San Antonio: Under the leadership of Dr. Ian Thompson, the University of Texas Health Science Center at San Antonio is participating in the Canary Foundation Prostate Active Surveillance Study.

University of Texas Southwestern Medical Center, Dallas Canary Foundation funds research in Dr. Adi Gazdar's group to identify biomarkers for risk assessment and early detection of lung cancer arising in individuals who have never smoked.

University of Washington, Seattle: Directed by Drs. Daniel Lin and Peter Nelson, the University of Washington is participating in the Canary Foundation Prostate Active Surveillance Study. Canary Foundation is providing financial support for a centralized repository to store samples collected as part of the Canary Prostate Active Surveillance Study. In addition, the Canary Foundation supports Dr. Teri Brentnall, whose research includes studying hereditary causes of pancreatic cancer and the development of blood-based markers for the early detection of pancreatic cancer.